title: [The efficacy of adefovir dipivoxil, entecavir and telbivudine for chronic hepatitis B treatment: a systematic review].
abstract: BACKGROUND
  Chronic hepatitis B is one of the most frequent infectious disease in the world and represents a serious problem of public health
  
  
  METHODS
  A systematic review of randomized clinical trials was conducted to evaluate the efficacy of the nucleoside/nucleotide analogues (adefovir, entecavir and telbivudine) used for the treatment of chronic hepatitis B. The databases PubMed and LILACS were consulted, among others
  
  
  RESULTS
  Twenty nine articles published between January/1970 to December/2009 were selected
  
  
  CONCLUSIONS
  All nucleoside/nucleotide analogues demonstrate upper or similar efficacy to lamivudine. The entecavir can be appropriate for patients with chronic hepatitis B, HBeAg positive and negative treatment-naive as alternative to lamivudine, considering its low potential of viral resistance. The addition of adefovir to lamivudine presented good results in lamivudine resistant patients. The use of entecavir and telbivudine in those patients presents risk of crossed resistance. TBV is one of the most recent antivirals available, but antiviral resistance already documented represents limitation to its use as therapeutic option to LAM. Adverse events of nucleoside/nucleotide analogues were similar in characteristics, gravity and incidence when compared to the lamivudina and placebo.
authors.affiliation: Programa de Pós-Graduação em Saúde Pública, Universidade Federal de Minas Gerais, Belo Horizonte, MG.
authors.forename: Alessandra Maciel
authors.initials: AM
authors.lastname: Almeida
authors.forename: Andréia Queiroz
authors.initials: AQ
authors.lastname: Ribeiro
authors.forename: Cristiane Aparecida Menezes de
authors.initials: CA
authors.lastname: Pádua
authors.forename: Cristina Mariano Ruas
authors.initials: CM
authors.lastname: Brandão
authors.forename: Eli Iôla Gurgel
authors.initials: EI
authors.lastname: Andrade
authors.forename: Mariângela Leal
authors.initials: ML
authors.lastname: Cherchiglia
authors.forename: Ricardo Andrade
authors.initials: RA
authors.lastname: Carmo
authors.forename: Francisco de Assis
authors.initials: Fde A
authors.lastname: Acurcio
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D009705:Nucleosides / Q000627:therapeutic use*; D063065:Organophosphonates / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000077712:Telbivudine; D013936:Thymidine / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D009705:Nucleosides; D063065:Organophosphonates; D011744:Pyrimidinones; D000077712:Telbivudine; C413685:entecavir; D006147:Guanine; D000225:Adenine; C106812:adefovir dipivoxil; D013936:Thymidine